Compare LXFR & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | FLGT |
|---|---|---|
| Founded | 1898 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.5M | 511.0M |
| IPO Year | 2002 | 2016 |
| Metric | LXFR | FLGT |
|---|---|---|
| Price | $17.22 | $21.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | ★ 382.5K | 257.6K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $384,600,000.00 | $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | $5.01 | $12.18 |
| P/E Ratio | $55.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.26 | $13.46 |
| 52 Week High | $19.45 | $31.04 |
| Indicator | LXFR | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 67.06 |
| Support Level | $16.68 | $19.12 |
| Resistance Level | $17.38 | $21.56 |
| Average True Range (ATR) | 0.06 | 0.60 |
| MACD | -0.00 | 0.17 |
| Stochastic Oscillator | 21.95 | 89.26 |
Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.